Clinilabs Expands Phase I Facility
Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit.
CLINILABS EXPANDS PHASE I FACILITY
New York, NY (August 6, 2008) – Clinilabs, Inc., a specialty contract research organization (CRO), has completed expansion of its Phase I unit. This expansion brings the Company’s Phase I facility to 68-beds, which includes two new large observation rooms that can accommodate up to four beds each, or up to 12 PK seats.
The Company conducts Phase I studies in any therapeutic area, including pharmacokinetic (PK), pharmacodynamic (PD), bioavailability (BA), bioequivalence (BE), drug interaction, and food interaction studies. Additionally, Clinilabs offers specialty services for complex PD studies, such as those that involve the collection of mood, cognition, psychomotor functioning, EEG, quantitative EEG, evoked potential (EP), and imaging data.
“Phase I studies are becoming increasingly complex and sponsors depend on data from these studies to make crucial decisions about their development programs,” stated Dr. Gary Zammit, President and CEO of Clinilabs. “Clinilabs’ state-of-the-art facility is an ideal location for pharmaceutical and biotechnology companies looking for outstanding service for their Phase I studies,” he added.
Conveniently located in New York City, Clinilabs can recruit patients from a large and diverse population, including healthy adult, healthy elderly, Japanese, Chinese, and key patient populations. In addition, Clinilabs’ metropolitan location provides sponsors, as well as patients, with easy access to transportation hubs and major subway and bus lines.
Clinilabs Phase I facility is staffed with highly qualified physicians, nurses, and research associates, providing service 24 hours a day, 7 days a week.
About Clinilabs, Inc.
Clinilabs is a specialty contract research organization (CRO) that provides a full portfolio of services to pharmaceutical, biotechnology, and medical device companies involved in the development of central nervous system (CNS) and cardiovascular (CV) therapeutics. The Company also provides early phase services in a wider range of therapeutic areas at its Phase I facility. Established in 2001, Clinilabs has provided services to more than one third of the world’s top 20 pharmaceutical companies, and has been involved in 7 successful New Drug Applications (NDAs) in central nervous system (CNS) and cardiovascular (CV) indications. For more information, please visit www.clinilabs.com <
http://www.clinilabs.com/
> .
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
